Johnson & Johnson

IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also…

This article first appeared on GuruFocus. Johnson & Johnson (NYSE:JNJ), the healthcare heavyweight behind blockbuster medicines and medical…

No surprises on inflation and new financing developments in the artificial intelligence trade drove the record-breaking action on…

CNBC’s Jim Cramer said Tuesday that Wall Street is taking profits in this year’s biggest AI infrastructure winners…

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…

CNBC’s Jim Cramer on Tuesday emphasized the importance of diversifying beyond the market’s hottest artificial intelligence winners. “I…

Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement…

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…

Johnson & Johnson shares fell Tuesday despite a mostly strong second-quarter earnings report and an increase to its…

Johnson & ⁠Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from…

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients